Pyroptotic pores reopen the case for caspase inhibitors.

Caspase inhibitors have repeatedly entered clinical trials but have not reached clinical practice due to toxicity and limited efficacy. Groborz and colleagues now show that gasdermin D pores admit otherwise membrane-impermeable inhibitors into pyroptotic cells, turning poor permeability into a mechanism of cell-state selectivity.